KDR and neoplasm: Currently, the mechanism by which the majority of anti‐angiogenic drugs prevent tumour angiogenesis is by inhibiting the VEGF or VEGF/VEGFR signalling pathway, causing tumour cells to ‘starve’ by disrupting its blood supply.27